Nature Reviews Drug Discovery 9, 57-67 (January 2010) | doi:10.1038/nrd3010

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

Aimee L. Jackson1 & Peter S. Linsley1  About the authors


Small interfering RNAs (siRNAs) are widely used to study gene function owing to the ease with which they silence target genes, and there is considerable interest in their potential for therapeutic applications. In a remarkably short time since their discovery, siRNAs have entered human clinical trials in various disease areas. However, rapid acceptance of the use of siRNAs has been accompanied by recognition of several hurdles for the technology, including a lack of specificity. Off-target activity can complicate the interpretation of phenotypic effects in gene-silencing experiments and can potentially lead to unwanted toxicities. Here, we describe the types of off-target effects of siRNAs and methods to mitigate them, to help enable effective application of this exciting technology.

Author affiliations

  1. Regulus Therapeutics, Inc., 1896 Rutherford Rd, Carlsbad, California 92008, USA.
    Email:; Email:


These links to content published by NPG are automatically generated.


RNAi in moderation

Nature Biotechnology News and Views (01 Jul 2006)

RNA interference has second helpings

Nature Biotechnology News and Views (01 Mar 2007)

See all 6 matches for News And Views